Form 4: Merit Medical Systems CEO Sells Shares Under Pre-Arranged Trading Plan

Merit Medical Systems Inc. President and CEO, Fred P. Lampropoulos, reported the sale of 400 shares of common stock for $95.61 per share, executed under a Rule 10b5-1 trading plan.

Summary

• Fred P. Lampropoulos, President and CEO of Merit Medical Systems Inc. (MMSI), sold 400 shares of common stock on June 10, 2025.
• The shares were sold at a price of $95.61 per share.
• This transaction was conducted under a Rule 10b5-1(c) pre-arranged trading plan, indicating it was scheduled in advance and not based on immediate, non-public information.
• Following the sale, Mr. Lampropoulos directly holds 1,045,628 shares of common stock.
• Additionally, he indirectly holds 7,734.258 shares through his spouse, 97,892 shares through a 401(k) Plan (as of May 30, 2025), and 90 shares through his spouse as custodian for a child, totaling 105,716.258 indirect shares.
• Mr. Lampropoulos also holds various non-qualified stock options, including 159,151 options at an exercise price of $55.73, 100,334 options at $37.71, 58,083 options at $56.25, and 54,302 options at $70.58, along with 2,000 options held indirectly by his spouse.

Sentiment

Score: 4

Explanation: The sale of a small number of shares by a CEO, even under a 10b5-1 plan, can be perceived as a minor negative signal by investors. However, the pre-planned nature of the sale and the CEO's substantial remaining direct and indirect holdings, along with significant unexercised options, mitigate a strong negative sentiment.

Positives

• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-scheduled sale not based on immediate, non-public information, which can alleviate concerns about insider sentiment.
• Despite the sale, the CEO retains a substantial direct beneficial ownership of 1,045,628 shares, demonstrating continued significant alignment with shareholder interests.
• The CEO also holds a large number of unexercised stock options (totaling 373,870), providing further incentive for long-term company performance.

Negatives

• A sale of shares by a high-ranking executive, even if pre-planned, can sometimes be perceived negatively by the market as it reduces their direct equity stake, potentially signaling a lack of confidence or a desire for personal diversification.

Risks

• Forfeiture of unvested options: An original grant of 10,000 options to the spouse was subject to forfeiture if not vested by June 22, 2020, with 8,000 options having been forfeited.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic outlook, as it is solely a report of an insider transaction.

Industry Context

This Form 4 filing details an individual executive's stock transaction and does not provide information relevant to broader industry trends or competitive analysis within the medical devices or healthcare sector.

Related Party Transactions

• The filing indicates indirect beneficial ownership by the reporting person's spouse (7,734.258 shares and 2,000 options) and through a 401(k) plan (97,892 shares), which are common related party disclosures in insider transaction reports.

Stakeholder Impact

• Shareholders: The sale of a small number of shares by the CEO might lead to minor concerns about insider sentiment, but the pre-planned nature and substantial remaining holdings suggest no significant negative impact on shareholder confidence.
• Employees, Customers, Suppliers, Creditors: This filing is unlikely to have any direct impact on these stakeholders as it pertains solely to an executive's personal stock transaction.

Key Dates

Recommendation

Keywords

Merit Medical Systems, MMSI, SEC Form 4, Insider Trading, Stock Sale, Executive Compensation, Fred P. Lampropoulos, Rule 10b5-1, Common Stock, Stock Options